Company Filing History:
Years Active: 2022
Title: Farshid Dayyani: Pioneering Innovations in Cancer Treatment
Introduction: Farshid Dayyani is an innovative inventor based in Irvine, California, recognized for his contributions to the field of cancer treatment. His groundbreaking work has resulted in the development of a method that significantly enhances the identification of individuals suited for chemotherapy.
Latest Patents: Dayyani holds a patent titled "Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses." This patent focuses on the utilization of specific biomarker molecules, namely cytokeratin-19 fragments and carcinoembryonic antigen, to accurately identify patients with non-small cell lung carcinoma who would benefit from chemotherapy. The methodology offers a promising approach to personalized cancer treatment.
Career Highlights: Farshid Dayyani currently works at Roche Diagnostics Operations, Inc., where he applies his expertise to develop effective diagnostic solutions. His innovative approach aligns with the company's mission to deliver cutting-edge healthcare technologies that enhance patient outcomes.
Collaborations: Dayyani collaborates with renowned professionals in the field, including Friedemann Krause and Vinzent Rolny. Their combined efforts reflect a commitment to advancing research and improving methodologies in cancer diagnostics and treatment.
Conclusion: Farshid Dayyani's contributions to the field of oncology, particularly through his patented methods for identifying chemotherapy candidates, exemplify the spirit of innovation that drives progress in medical research. His work at Roche Diagnostics Operations, Inc. and collaborations with esteemed colleagues signify a dedicated pursuit of advancements that hold the potential to save lives and improve patient care.